관리-도구

편집 파일: 1645088477.M660763P17647.server.saraya-global.com,S=13050,W=13263:2,

Envelope-to: roya.rouzbehani@saraya.world
Delivery-date: Thu, 17 Feb 2022 17:01:17 +0800
Content-Type: text/html; charset=utf-8
From: Office WulfHoeflich <office.wulfhoeflich@futurebridgeglobal.com>
Subject: Unique Insights on Techno Commercial Trends for Disease Pattern &
 Therapeutics in Cardio Metabolic & Endocrine
Message-ID: <028d43e1-84a1-d99e-9502-95c0134128f2@futurebridgeglobal.com>
Content-Transfer-Encoding: quoted-printable
Date: Thu, 17 Feb 2022 09:00:28 +0000 (UTC)
MIME-Version: 1.0
Reply-To: office.wulfhoeflich@futurebridgeglobal.com
To: roya.rouzbehani@saraya.world

Dear roya,</=
span> My name is Wu=
lf H=C3=B6flich and I head the Business Development for FutureBridge - a Re=
search & Advisory firm providing techno-commercial insights across major in=
dustries for over two decades. We support the most Fortune 5=
00 players like Roche, DSM, Reckitt Benckiser, STADA, Nestle, Clar=
iant, 3M, BASF, etc. I am w=
riting to you as we have a unique proposition for SARYRA<s=
trong> on the Evolving Disease Pattern & Therapeutics in the area =
of Cardio Metabolic & Endocrine and we believe that reachi=
ng out to you would be most advisable given the ambit and responsibility of=
 your profile. We are keen to intr=
oduce ourselves and share with you how companies are evaluating opportuniti=
es to identify and scientifically compare different biomarkers & ta=
rgets, novel treatment modalities, and associated=
 intellectual property. We shall also exhibit cases of evolving pat=
ient journey, impact of clinical guidelines on referral pa=
thways, treatment algorithms, rising expectations=
 of standard of care (SoC) across different lines of thera=
py and similar other cases. =
It will be interesting for you to see how sci=
entific intelligence program is being used by Innovation, R&D, Technology s=
couting, Strategy, M&A and Clinical development functions of leading Biopha=
rma & Medtech companies to understand and act on complex therapeutic areas =
such Cardiovascular & Metabolic Health and indications lik=
e Hypertension, Diabetes (T1, T2 & Gestat=
ional), PAH, Hypercholosterolmia, Arrhythmias, Congenial =
heart disease, Cardiomyopathy, Rheumatic Heart Diseases, CAD, Thyroid, and =
more. We would like to request thirty minutes of your tim=
e for a digital meeting (30 minutes only) in the coming weeks to introduce =
to you our unique hyper intelligence and insights program on Animal Health =
& Therapeutics. Would any of the following slots work for you? I=
f yes, please write back to me with your preference. If not, please suggest=
 alternatives: 
 <table style=3D"font-family: Arial,Helvetica,sans-serif; font-size: 14=
px; border-collapse: collapse;">
 <tbody>
 =20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Thursday</td>
 <td style=3D"width: 68.2977%;"> 24 February - 0=
7.00 to 07.30 CET </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Friday</td>
 <td style=3D"width: 68.2977%;"> 25 February - 0=
8.00 to 08.30 CET </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Monday</td>
 <td style=3D"width: 68.2977%;"> 28 February - 0=
7.00 to 07.30 CET </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Tuesday</td>
 <td style=3D"width: 68.2977%;"> 01 March - 08.0=
0 to 08.30 CET </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Wednesday</td>
 <td style=3D"width: 68.2977%;"> 02 March - 09.0=
0 to 09.30 CET </td>
 </tr>
 </tbody>
 </table> 
Best Regards, Wulf H=C3=B6flich SVP =E2=80=93 Business Development - Dipl.-Ing. (Univ.) FutureBridge UK 5, Chancery Lane, London EC4A 1BL United Kingdom T :+44 2034 787 710 <a href=3D=
"http://insidertrends.futurebridge.com/r/a310bbb4f9030d6a824e14202?ct=3DYTo=
1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjExOD=
k1O31zOjU6ImVtYWlsIjtpOjE5OTI3O3M6NDoic3RhdCI7czoyMjoiNjIwZGY0NmQ5NGYxNTY1N=
jQwOTc0MyI7czo0OiJsZWFkIjtzOjg6IjExNTY0MDM2IjtzOjc6ImNoYW5uZWwiO2E6MTp7czo1=
OiJlbWFpbCI7aToxOTkyNzt9fQ%3D%3D&"></a> <a href=3D"http://insidertre=
nds.futurebridge.com/r/a310bbb4f9030d6a824e14202?ct=3DYTo1OntzOjY6InNvdXJjZ=
SI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjExODk1O31zOjU6ImVtYWls=
IjtpOjE5OTI3O3M6NDoic3RhdCI7czoyMjoiNjIwZGY0NmQ5NGYxNTY1NjQwOTc0MyI7czo0OiJ=
sZWFkIjtzOjg6IjExNTY0MDM2IjtzOjc6ImNoYW5uZWwiO2E6MTp7czo1OiJlbWFpbCI7aToxOT=
kyNzt9fQ%3D%3D&">www.futurebridge.com</a> 
<img src=3D"https://insidertrends.futurebridge.com/media/images/fb_logo.=
jpg" />
 
Please consider the environment before printing this email.</sp=
an> FutureBridge=C2=AE =
is a registered trademark of Cheers Interactive (India) Private Limited. <b=
r /> =E2=80=9CThis message is intended only for the person or en=
tity to which it is addressed and contains confidential, proprietary and/or=
 privileged information. If you have received this message in error, please=
 notify the sender immediately and delete this message from your system. Re=
asonable precautions have been taken to ensure that this message is virus-f=
ree. However, Cheers Interactive (India) Private Limited does not accept an=
y responsibility whatsoever for any loss or damage arising from the use of =
this message or any attachments herein=E2=80=9D. =

<div style=3D"text-align: center;">
 FutureBridge, Stadsplateau 7 ,Ultrecht, =
3521 AZ, Ultrecht, The Netherlands<a href=3D"http://insidertren=
ds.futurebridge.com/email/unsubscribe/620df46d94f15656409743_____unsubscrib=
e_____Meeting%20Ask_____MtgAsk- Cardio Metabolic Endo - 34 - 220217 - MDB R=
erun Batch ">Unsubscribe</a> <a href=3D"http://insidertrends.futur=
ebridge.com/email/unsubscribe/620df46d94f15656409743_____preference_____Mee=
ting%20Ask_____MtgAsk- Cardio Metabolic Endo - 34 - 220217 - MDB Rerun Batc=
h ">Manage Preferences</a>
</div><img height=3D"1" width=3D"1" src=3D"http://insidertrends.futurebridg=
e.com/email/620df46d94f15656409743.gif" alt=3D"" />